Search research articles
Contact Us
Filters
Showing results (291-300 of 326) with videos related to
Page
of 33
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2017
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)
Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann, et al.
Blood
|
February 19, 2016
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000
Anja Möricke, Martin Zimmermann, Maria Grazia Valsecchi, et al.
Blood
|
September 24, 2017
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL
Franco Locatelli, Maria Grazia Valsecchi, Anja Möricke, et al.
Leukemia
|
December 7, 2019
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial
Andishe Attarbaschi, Georg Mann, Martin Zimmermann, et al.
The Journal of Clinical Investigation
|
August 12, 2020
Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities
Chiara F Magnani, Giuseppe Gaipa, Federico Lussana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2023
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study
Valentino Conter, Maria Grazia Valsecchi, Gunnar Cario, et al.
Hemasphere
|
September 4, 2025
Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapy
Gunnar Cario, Maria Grazia Valsecchi, Valentino Conter, et al.
The Lancet. Haematology
|
June 25, 2021
Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia
Liv Andrés-Jensen, Andishe Attarbaschi, Edit Bardi, et al.
The New England Journal of Medicine
|
January 31, 2009
Gene therapy for immunodeficiency due to adenosine deaminase deficiency
Alessandro Aiuti, Federica Cattaneo, Stefania Galimberti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2021
Clinical Implications of Minimal Residual Disease Detection in Infants With <i>KMT2A</i>-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
Janine Stutterheim, Inge M van der Sluis, Paola de Lorenzo, et al.
Page
of 33
Search research articles
Search
Showing results (291-300 of 326) with videos related to
Sort By:
Page
of 33
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2017
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)
Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann, et al.
Blood
|
February 19, 2016
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000
Anja Möricke, Martin Zimmermann, Maria Grazia Valsecchi, et al.
Blood
|
September 24, 2017
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL
Franco Locatelli, Maria Grazia Valsecchi, Anja Möricke, et al.
Leukemia
|
December 7, 2019
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial
Andishe Attarbaschi, Georg Mann, Martin Zimmermann, et al.
The Journal of Clinical Investigation
|
August 12, 2020
Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities
Chiara F Magnani, Giuseppe Gaipa, Federico Lussana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2023
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study
Valentino Conter, Maria Grazia Valsecchi, Gunnar Cario, et al.
Hemasphere
|
September 4, 2025
Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapy
Gunnar Cario, Maria Grazia Valsecchi, Valentino Conter, et al.
The Lancet. Haematology
|
June 25, 2021
Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia
Liv Andrés-Jensen, Andishe Attarbaschi, Edit Bardi, et al.
The New England Journal of Medicine
|
January 31, 2009
Gene therapy for immunodeficiency due to adenosine deaminase deficiency
Alessandro Aiuti, Federica Cattaneo, Stefania Galimberti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2021
Clinical Implications of Minimal Residual Disease Detection in Infants With <i>KMT2A</i>-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
Janine Stutterheim, Inge M van der Sluis, Paola de Lorenzo, et al.
Page
of 33